Plasma FFA oxidation (measured by infusion of 14C-palmitate) and net lipid oxidation (indirect calorimetry) are both inhibited by insulin. The present study was designed to examine whether these insulin-mediated effects on lipid metabolism resulted from a decline in circulating FFA levels or from a direct action of the hormone on FFA/lipid oxidation. Nine subjects participated in two euglycemic insulin clamps, performed with and without heparin. During each insulin clamp study insulin was infused at two rates, 4 and 20 mU/mi2 min for 120 min. The studies were performed with indirect calorimetry and 3-3H-glucose and '4C-palmitate infusion. During the control study plasma FFA fell from 610±46 to 232±42 to 154±27 ;tmol/ liter, respectively. When heparin was infused basal plasma FFA concentration remained constant. During the control study, FFA/lipid oxidation rates decreased in parallel with the fall in the plasma FFA concentration. During the insulin/heparin study, plasma 14C-FFA oxidation remained unchanged while net lipid oxidation decreased. In conclusion, when the plasma FFA concentration is maintained unchanged by heparin infusion, insulin has no direct effect on FFA turnover and disposal. These results thus suggest that plasma FFA oxidation is primarily determined by the plasma FFA concentration, while net lipid oxidation is regulated by both the plasma FFA and the insulin level. (J. Clin. Invest. 1991. 87:83-89.)
Introduction
In normal and diabetic subjects insulin is known to suppress lipid oxidation as measured by indirect calorimetry (1, 2) . However, indirect calorimetry measures net lipid oxidation which includes both oxidation of plasma FFA and oxidation of intracellular lipids (3) (4) (5) . The oxidation of plasma FFA, which can be measured with '4C-labeled palmitate, is inhibited by small increments in the plasma insulin concentration (6, 7) . The decrease in FFA oxidation could result from decreased substrate level, secondary to an inhibition of lipolysis, or could result from a direct effect of insulin on FFA oxidation. Because both lipolysis and FFA oxidation may be regulated in concert by insulin, it is difficult to draw conclusions about the effect(s) of insulin on lipid/FFA oxidation when the plasma FFA concentration is changing. To circumvent this problem, we have examined the effect of insulin on lipid/FFA oxidation under conditions where the plasma FFA concentration has been kept constant at the basal level by an infusion of heparin. A second aim of the study was to examine the effect ofdifferent FFA concentrations on the suppression of hepatic glucose production and stimulation of glucose disposal by insulin. Our data provide evidence that insulin has no direct effect on plasma FFA oxidation but markedly inhibits the oxidation of intracellular lipids.
Methods
Subjects. Nine healthy young subjects (seven males, two females) with a mean (±SEM) age of 22±1 yr and ideal body weight of 102±2% were studied. All subjects had a normal oral glucose tolerance test according to the revised criteria ofthe National Diabetes Data Group. The fasting plasma glucose was 86±1 mg/dl and fasting plasma insulin concentration was 7±1 uU/ml. None of the subjects had any clinical or laboratory evidence of hepatic, renal, or other endocrine disease. All subjects were consuming a weight-maintaining diet containing at least 200 g of carbohydrate per day for 2 wk before study. Before participating in the experimental protocol, the purpose, nature, and potential risks of the study were explained to all subjects and informed written voluntary consent was obtained. The study protocol was approved by the Human Investigation Committee of the Yale University School of Medicine.
Experimental protocol. All subjects participated in two experiments which were carried out in random order with a 2-wk interval. During the first experiment a two-step euglycemic insulin clamp (+4 and +20 mU/M2 _ min) was performed (8) with each insulin infusion lasting 120 min. The second experiment was similar to the first with one exception; at the beginning of the 4 mU/m2-min insulin infusion subjects received a primed (200 U)-continuous (25 U/min) infusion ofheparin to stimulate lipoprotein lipase. At the start of the second insulin infusion step (20 mU/M2_ min) subjects received a second heparin bolus (200 U) followed by a continuous infusion at 35 U/min. All studies were performed with indirect calorimetry and infusion of 3-3H-glucose and '4C-palmitate to quantitate respiratory gas exchange, hepatic glucose production, and FFA oxidation, respectively. The low insulin infusion protocol (4 mU/Mi2. min) was designed to examine whether differences in the plasma FFA concentration would influence the effect of insulin on the liver. The 20 mU/M2_ min insulin infusion protocol, on the other hand, allowed us to examine whether differences in the plasma FFA concentration would affect the capacity of insulin to stimulate peripheral glucose uptake.
Euglycemic insulin clamp. The subjects were admitted to the Clinical Research Center on the morning ofstudy. All studies were initiated at 0800 after a 12-h overnight fast. Before the study Teflon catheters were inserted into an antecubital vein for infusion of test substances and retrogradely into a wrist vein for withdrawal ofblood samples. The hand was then inserted into a heated box (70°C) to achieve arterialization of venous blood. After obtaining four basal samples for insulin, crystalline porcine insulin (Lilly, Indianapolis, IN) was started to acutely raise and maintain the plasma insulin concentration at the desired level for 120 min. The plasma glucose concentration was determined every 5 min and a variable infusion of20% glucose was adjusted to maintain the plasma glucose concentration constant at the basal level (8) . At 120 min the insulin space was reprimed and the second insulin infusion (20 mU/m2 * min) started and maintained for another 120 min. Blood samples for plasma insulin and FFA concentrations were drawn at 15-min intervals.
Tritiated glucose. At 150 min before the start of insulin, a primed (25 uCi)-continuous (0.25 XCi/min) infusion of 3-3H-glucose (New England Nuclear, Boston, MA) was begun. Baseline samples for determination of 3-3H-glucose specific activity were drawn at 5-min intervals during the last 30 min of the equilibration period. During the insulin clamp, 3-3H-glucose samples were drawn at 15-min intervals until the last 20 min, during which time they were obtained at 5-min intervals. All subjects achieved a steady-state level of plasma tritiated glucose specific activity at the end of the basal equilibration period.
FFA turnover. 14C-Palmitate (New England Nuclear) was utilized to quantitate plasma FFA turnover (6, 9) . A priming dose of 2.5 gCi 14C-palmitate was injected 150 min before the first insulin infusion and this was followed by a constant infusion at 0. 
Analytical determinations
Plasma glucose was determined in duplicate by the glucose oxidase method on a glucose analyzer II (Beckman Instruments, Inc., Fullerton, CA). Methods for determination of plasma tritiated glucose specific activity have been published previously (I 1). Blood for determination of insulin, FFA and '4C-FFA specific activity was sampled into prechilled tubes and immediately centrifuged. Plasma insulin was measured by specific radioimmunoassay (12) , urinary nitrogen excretion by the method of Kjeldahl (13) , and plasma FFA concentrations were measured by the microfluorometric method of Miles et al. (14) . The method for determination of '4C-FFA specific activity in plasma has been described in detail previously (6 Intracellular (unlabeled) FEA oxidation was calculated as the difference between net lipid oxidation (indirect calorimetry) and plasma FFA oxidation. It should be noted that this represents a minimal estimate of intracellular FFA oxidation because net lipid oxidation, as determined by indirect calorimetry, equals the difference between lipid oxidation and lipid synthesis.
Statistical analysis
Data are presented as mean±SEM. Significance ofdifferences between the two experiments was calculated with analysis ofvariance. Pearson's correlation coefficients were calculated by standard formulae.
Results
Plasma glucose, insulin, and FFA concentrations. The fasting plasma glucose concentration during the control and heparin experiments was 86±2 and 85±2 mg/dl, respectively. The mean plasma glucose during the 4 and 20 mU/mi2 min insulin clamp steps of both studies was similar and averaged 84±2 mg/dl. The coefficients of variation ofthe plasma glucose were 3.9±0.5% and 3.7±0.5%, respectively, during control and heparin experiments. The fasting plasma insulin concentration during the control study was 6±1 AtU/ml and rose to I I± and 36±2 MU/ml, respectively, during the 4 and 20 mU/M2_ min insulin clamp steps (Fig. 2) . The basal plasma insulin concentration in the heparin experiment was 7±1 gU/ml and rose to 11i 1 and 36±2 uU/ml, respectively. The coefficients of variation in plasma insulin during the control and the heparin experiment were 7.4±0.8% and 7.5±0.9%, respectively.
The basal plasma FFA concentration during the control study was 610±46 ,mol/liter and fell to 232+42 and 154±27
,uU/liter, respectively, during the 4 and 20 mU/mi2 min insulin clamp steps (Fig. 2) . The basal plasma FFA concentration during the heparin study, 646±77 ,umol/liter was maintained at 725±129 and 524±100 Mtmol/liter, respectively, during the 4 and 20 mU/mi2 min insulin clamp steps. 6.46±0.6 gmol/kg. min) (Fig. 3) (Fig. 4) (Fig. 4) . During the 4 and 20 mU/Mi2. min insulin clamp steps of the control study the basal rate of nonoxidative FFA metabolism declined by 51 and 62%, respectively. When the plasma FFA concentration was maintained at the fasting level with heparin, the rate of nonoxidative FFA metabolism declined slightly, although not significantly from baseline and remained greater than during the control experiment (P < 0.01).
During both control and heparin studies plasma FFA concentration was strongly correlated with the rate of plasma FFA oxidation (r = 0.71; P < 0.001; n = 54) (Fig. 5) , with the rate of nonoxidative FFA disposal (r = 0.84; P < 0.001), and weakly with the rate of net lipid oxidation (r = 0.31; P < 0.02). Glucose metabolism Hepatic glucose production (HGP). The basal rate of HGP was similar during the control and heparin studies (2.0±0.13 and 1.90±0.08 mg/kg. min) (Fig. 6) . During low-dose insulin infusion, HGP was reduced by 50% in control and heparin experiments (to 1.03±0.13 and 1. 19±0.18 mg/kg . min, respectively). During the 20 mU/m2. min insulin infusion, HGP was completely suppressed in both experiments.
Total glucose disposal. In the basal state the rate of glucose disposal equals the rate of glucose appearance (HGP) and was similar in control and heparin studies (Fig. 6 ). There was no significant enhancement of glucose disposal during the 4 mU/ m2 . min insulin infusion in either the control or heparin stud- (Fig. 7) . During low-dose insulin infusion, there was no significant change in the rate ofglucose oxidation in the control study (1.55±0.15 mg/kg-min), whereas there was a slight reduction during the heparin study (1.19±0.20 mg/ kg-min; P < 0.05 when comparing the change from basal between the two experiments). During the 20 mU/m2. min insulin infusion, the rate of glucose oxidation was significantly reduced during the heparin vs. control study (2.80±0.35 vs. 3.71±0.24 mg/kg. min; P < 0.05).
Nonoxidative glucose metabolism. The basal rate of nonoxidative glucose metabolism was similar in the two experiments (0.48±0.12 vs. 0.32±0.14 mg/kg . min) (Fig. 7) . There was no significant change in the rate of nonoxidative glucose metabolism during the low-dose insulin infusion in the control study (0.79±0.22 mg/kg-min), whereas there was an increase in the heparin study (1.19±0.36; P < 0.05). Although the rate ofnonoxidative glucose disposal was enhanced during the 20 mU/ m2. min insulin infusion in both the control and the heparin studies, there was no significant difference between the control and the heparin study (3.81±0.66 vs. 4 .18±0.65 mg/kg -min). 
Discussion
In the present study we have examined the independent effects of insulin and FFA on total lipid oxidation, measured by indirect calorimetry, and plasma FFA oxidation, measured by 14C-palmitate. When insulin was infused to create physiologic increments in the plasma insulin concentration (36±2 ,gU/ml), both net lipid oxidation and plasma FFA oxidation declined in parallel. However, because the plasma FFA concentration also declined during the infusion of insulin, it was not possible to define whether the decline in plasma FFA/net lipid oxidation was due to a direct inhibitory effect ofinsulin or to a decrease in substrate delivery. To distinguish between these two possibilities, the plasma FFA concentration was "clamped" at the basal level by an infusion of heparin to activate lipoprotein lipase. Under these conditions insulin failed to inhibit plasma FFA oxidation but decreased net lipid oxidation by > 60%. These results point at the existence of two distinct lipid pools which share the same oxidative pathway but whose input into this oxidative pathway is differentially regulated by insulin and plasma FFA supply. Oxidation of 14C-palmitate primarily reflects the circulating plasma FFA pool (4, 5, 19) and is unaffected by insulin. In contrast, net lipid oxidation reflects both circulating plasma FFA as well as a large intracellular FFA pool, whose oxidation is sensitive to physiologic changes in the plasma insulin concentration.
In the basal state plasma FFA oxidation accounted for only 40-50% of net lipid oxidation. Our results indicate that the remaining 50-60% is derived from oxidation of intracellular lipids, which are not in equilibrium with the plasma FFA pool and therefore are not traced by the i4C-palmitate. Similar data have been reported by Issekutz et al. (5) Robin et al. (19) in nutritionally depleted patients who were suffering from acute infection or injury.
Consistent with the concept of a large intracellular lipid pool, Eaton et al. have shown that the plasma FFA pool exchanges with a 100 larger tissue pool, the bulk ofwhich resides within the liver and muscle (20) . Further support for this view has been provided by George and Naik, who demonstrated abundant lipid deposits in resting muscle (21) . Hydrolysis of these intramuscular triglycerides/phospholipid stores with their subsequent intramuscular oxidation, or hydrolysis of lipoproteins in the capillary bed with immediate oxidation by adjacent muscle tissues, could explain the large discrepancy between total lipid oxidation and plasma FFA oxidation (22) .
From the present results it can be concluded that physiologic increments in the plasma insulin concentration do not have a direct effect on the oxidation of circulating FFA. The plasma FFA concentration appears to be the main determinant of its own rate of oxidation. Several observations support this conclusion. First, inhibition of lipolysis by physiologic hyperinsulinemia causes a concomitant decline in the plasma FFA oxidation rate, which closely parallels the decline in plasma FFA concentration. Second, when the plasma FFA concentration was maintained constant by an infusion of heparin, the rate of plasma FFA oxidation was uninfluenced by insulin. Third, the plasma FFA concentration showed a strong positive correlation with the rate ofplasma FFA oxidation and a similar correlation has been reported in dogs (10) . Lastly, in vitro experiments have demonstrated that the rate of FFA oxidation increases in proportion to the increase in medium FFA concentration (23 (20) . Second, a positive correlation has been shown between the rate of FFA turnover and the appearance of FFA in triglycerides in dogs (25) and in man (26, 27) . Third, glucose feeding in normal subjects leads to a decrease in plasma FFA concentration and a concomitant reduction in the rate of FFA reesterification (19) . The present results also provide some interesting information concerning the interaction between lipid/FFA and glucose metabolism. More than 20 years ago Randle and co-workers developed the concept of substrate competition, i.e., an increase in FFA oxidation leads to a decrease in glucose oxidation and vice versa (28) . We previously have shown in normal subjects that the infusion of Intralipid during an insulin clamp resulting in a twofold increase in the basal plasma FFA concen-tration caused a significant reduction in the rates of oxidative and nonoxidative glucose disposal (29) . In addition, the ability of hyperglycemia to inhibit basal HGP was impaired (29) . In the present study, when the plasma FFA concentration was maintained constant at the basal level by heparin, the stimulatory effect of insulin on glucose oxidation was reduced, while nonoxidative glucose disposal remained unchanged. The results indicate, that providing more substrate for FFA oxidation under these conditions will only decrease the amount of glucose oxidized leaving the nonoxidative pathway unaffected. Furthermore, maintaining the FFA concentration unchanged at the basal level with heparin does not affect the inhibitory effect of insulin on HGP.
In summary, the data demonstrate that insulin has no direct effect on turnover and disposal of FFA when the plasma FFA concentration is maintained unchanged. They further suggest that oxidation of FFA from plasma and from intracellular lipid stores are differently regulated. Whereas the oxidation ofplasma FFA is primarily determined by the plasma FFA concentration, the regulation of intracellular FFA oxidation is more complex and dependent upon both the plasma FFA and insulin concentration.
